Loading
HKSEHealthcareBiotechnology
Latest quote
HK$13.38
+HK$0.49 · +3.80%
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Latest quote
HK$13.38
+HK$0.49 · +3.80%
Regular session · HKT · Market data may be delayed.
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Day range
Current HK$13.38
52-week range
Current HK$13.38
Regular session · HKT · Market data may be delayed.
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Day range
Current HK$13.38
52-week range
Current HK$13.38
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 158.21M USD | 38.1M USD | 89.5M USD | 40.66M USD | 4.31M USD |
| Cost of goods sold | 11.08M USD | 4.49M USD | 2.03M USD | 130K USD | 137K USD |
| Gross profit | 147.13M USD | 33.61M USD | 87.47M USD | 40.53M USD | 4.17M USD |
| Research and development | 38.13M USD | 21M USD | 45.08M USD | 135.14M USD | 107.1M USD |
| Selling, general, and administrative | 28.3M USD | 7.55M USD | 20.56M USD | 10.08M USD | 10.33M USD |
| Operating expenses | 66.43M USD | 37.31M USD | 65.64M USD | 161.86M USD | 147.17M USD |
| Interest income | 12.19M USD | 6.78M USD | 5.62M USD | 2.87M USD | 2.27M USD |
| Interest expense | 2.04M USD | 3.51M USD | 3.87M USD | 1.99M USD | 176K USD |
| Depreciation and amortization | 2.53M USD | 1.62M USD | 4.63M USD | 4.82M USD | 6.81M USD |
| Operating income | 80.7M USD | −3.7M USD | 21.83M USD | −121.89M USD | −143M USD |
| Net income | 91.47M USD | 2.78M USD | 22.8M USD | −137.27M USD | −137.88M USD |
Company facts updated Sep 14, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS14.52M0.00%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE Developed Markets ETFVEA9.71M0.00%315B USD0.03%$72.69+1.07%
iShares Core MSCI EAFE ETFIEFA7.89M0.00%194.75B USD0.07%$99.50+1.00%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS4.08M0.03%13.6B USD0.06%$158.56+0.72%
iShares MSCI EAFE Small-Cap ETFSCZ3.62M0.03%12.96B USD0.40%$86.09+0.87%
Schwab International Small-Cap Equity ETFSCHC2.52M0.04%5.68B USD0.06%$50.72+0.63%
State Street SPDR Portfolio Emerging Markets ETFSPEM2.21M0.01%17.86B USD0.07%$52.51+0.67%
Vanguard FTSE Pacific ETFVPL1.03M0.01%13.1B USD0.07%$118.1+1.98%Vanguard Total International Stock ETFVXUSVanguard FTSE Developed Markets ETFVEAiShares Core MSCI EAFE ETFIEFAVanguard FTSE All-World ex-US Small-Cap ETFVSSiShares MSCI EAFE Small-Cap ETFSCZSchwab International Small-Cap Equity ETFSCHCState Street SPDR Portfolio Emerging Markets ETFSPEMVanguard FTSE Pacific ETFVPLAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
